EP3992287A4 - Antigen prepared on basis of taking padi4 as tumor marker, and antibody and use thereof - Google Patents

Antigen prepared on basis of taking padi4 as tumor marker, and antibody and use thereof Download PDF

Info

Publication number
EP3992287A4
EP3992287A4 EP20944994.1A EP20944994A EP3992287A4 EP 3992287 A4 EP3992287 A4 EP 3992287A4 EP 20944994 A EP20944994 A EP 20944994A EP 3992287 A4 EP3992287 A4 EP 3992287A4
Authority
EP
European Patent Office
Prior art keywords
padi4
antibody
taking
basis
tumor marker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20944994.1A
Other languages
German (de)
French (fr)
Other versions
EP3992287A1 (en
Inventor
Xiaotian Chang
Xueyan LV
Dongxia YANG
Yanqiu XING
Yuxia GAO
Shili SHAO
Feng Liu
Junchao FENG
Jun Xing
Lin Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Xinchuang Biological Technology Co Ltd
Original Assignee
Shandong Xinchuang Biological Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Xinchuang Biological Technology Co Ltd filed Critical Shandong Xinchuang Biological Technology Co Ltd
Publication of EP3992287A1 publication Critical patent/EP3992287A1/en
Publication of EP3992287A4 publication Critical patent/EP3992287A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03015—Protein-arginine deiminase (3.5.3.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP20944994.1A 2020-07-13 2020-08-28 Antigen prepared on basis of taking padi4 as tumor marker, and antibody and use thereof Pending EP3992287A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010669810.1A CN111733151B (en) 2020-07-13 2020-07-13 Antigen and antibody prepared based on PADI4 as tumor marker and application
PCT/CN2020/112240 WO2022011800A1 (en) 2020-07-13 2020-08-28 Antigen prepared on basis of taking padi4 as tumor marker, and antibody and use thereof

Publications (2)

Publication Number Publication Date
EP3992287A1 EP3992287A1 (en) 2022-05-04
EP3992287A4 true EP3992287A4 (en) 2022-11-02

Family

ID=72654510

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20944994.1A Pending EP3992287A4 (en) 2020-07-13 2020-08-28 Antigen prepared on basis of taking padi4 as tumor marker, and antibody and use thereof

Country Status (5)

Country Link
US (1) US20220268777A1 (en)
EP (1) EP3992287A4 (en)
JP (2) JP7205964B2 (en)
CN (1) CN111733151B (en)
WO (1) WO2022011800A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3266872A1 (en) * 2015-03-06 2018-01-10 Public University Corporation Yokohama City University Novel anti-pad4 antibody
WO2019131769A1 (en) * 2017-12-26 2019-07-04 公立大学法人名古屋市立大学 Novel anti-pad4 antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101101290A (en) * 2006-11-30 2008-01-09 山东省医药生物技术研究中心 Tumour serum mark and its uses
RU2011101391A (en) * 2008-06-16 2012-08-10 Хираликс Б.В. (Nl) PEPTIDYLARGININDESYMINASE INHIBITORS (PAD)
JPWO2012026309A1 (en) 2010-08-23 2013-10-28 公立大学法人横浜市立大学 Creation of anti-PAD4 antibody drugs
WO2015144688A1 (en) 2014-03-25 2015-10-01 Ruprecht-Karls-Universität Heidelberg Host dependency factors as targets for antiviral therapy
CN105092844A (en) * 2015-07-10 2015-11-25 深圳市贝沃德克生物技术研究院有限公司 Pancreatic cancer protein biomarker detection kit and detection system
MA45112A (en) 2016-05-24 2019-04-10 Medimmune Ltd ANTI-PAD4 AUTO-ANTIBODIES AS BIOLOGICAL MARKERS OF CLINICAL RESPONSE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
CN113621706B (en) * 2017-06-22 2024-05-10 北海康成（北京）医药科技有限公司 Methods and kits for predicting the response of esophageal cancer to anti-ERBB 3 antibody therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3266872A1 (en) * 2015-03-06 2018-01-10 Public University Corporation Yokohama City University Novel anti-pad4 antibody
WO2019131769A1 (en) * 2017-12-26 2019-07-04 公立大学法人名古屋市立大学 Novel anti-pad4 antibody

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHANG XIAOTIAN ET AL: "Investigating the Pathogenic Role of PADI4 in Oesophageal Cancer", INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, vol. 7, no. 6, 1 January 2011 (2011-01-01), pages 769 - 781, XP055964548, ISSN: 1449-2288, DOI: 10.7150/ijbs.7.769 *
ISHIGAMI AKIHITO ET AL: "Two novel sandwich ELISAs identify PAD4 levels and PAD4 autoantibodies in patients with rheumatoid arthritis", MODERN RHEUMATOLOGY, vol. 23, no. 4, 2 July 2013 (2013-07-02), JP, pages 794 - 803, XP055964718, ISSN: 1439-7595, DOI: 10.3109/s10165-012-0748-0 *
NAKASHIMA KATSUHIKO ET AL: "PAD4 regulates proliferation of multipotent haematopoietic cells by controlling c-myc expression", NATURE COMMUNICATIONS, vol. 4, no. 1, 14 May 2013 (2013-05-14), XP055964574, Retrieved from the Internet <URL:http://www.nature.com/articles/ncomms2862> DOI: 10.1038/ncomms2862 *
WANG LIN ET AL: "Expression of Peptidylarginine Deiminase Type 4 in Ovarian Tumors", INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 1 January 2010 (2010-01-01), pages 454 - 464, XP055964545, ISSN: 1449-2288, DOI: 10.7150/ijbs.6.454 *

Also Published As

Publication number Publication date
JP2022537074A (en) 2022-08-23
CN111733151A (en) 2020-10-02
JP7460196B2 (en) 2024-04-02
EP3992287A1 (en) 2022-05-04
CN111733151B (en) 2021-11-12
JP2023030115A (en) 2023-03-07
US20220268777A1 (en) 2022-08-25
JP7205964B2 (en) 2023-01-17
WO2022011800A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
EP3740510A4 (en) Multispecific antigen binding proteins and methods of use thereof
EP3797124A4 (en) Anti-ror1 antibody and use thereof
EP3852805A4 (en) Anti-lilrb2 antibodies and methods of use thereof
EP4031177A4 (en) Anti-tnfr2 antibodies and methods of use
EP3907240A4 (en) Anti-tnfr2 antibody and use thereof
EP3915581A4 (en) Novel cancer antigens and antibodies of said antigens
ZA202105285B (en) Antibody against human il-4ra and use thereof
EP3985025A4 (en) Antibody to tigit and use thereof
EP3808774A4 (en) Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof
EP3851455A4 (en) Monoclonal antibody specifically binding human and monkey cd38 antigen, and preparation method therefor and application thereof
EP3930756A4 (en) Lilrb4-binding antibody and methods of use thereof
EP3743447A4 (en) B7-h4 antibodies and methods of use thereof
EP3962956A4 (en) Anti-hvem antibodies and use thereof
EP3757122A4 (en) Monoclonal antibody capable of specifically binding human plasmalemma vesicle-associated protein pv-1, as well as preparation method and use thereof
EP3962953A4 (en) Cancer associated antibody compositions and methods of use
EP3892639A4 (en) Cd3 antibody and pharmaceutical use thereof
EP3992211A4 (en) Anti-cea antibody and application thereof
EP3981793A4 (en) Ceacam5-resistant monoclonal antibody and preparation method thereof and use thereof
EP4071172A4 (en) Anti-lilrb1 antibody and uses thereof
EP3902840A4 (en) Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
EP3983450A4 (en) Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof
EP3813878A4 (en) Anti-bcma car antibodies, conjugates, and methods of use
EP3746484A4 (en) Anti-ms4a6a antibodies and methods of use thereof
EP3778638A4 (en) Antibody binding specifically to ecl-2 of claudin 3, fragment thereof, and use thereof
EP3896086A4 (en) Anti-il-17a antibody and use thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20221005

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20220928BHEP

Ipc: C07K 16/40 20060101ALI20220928BHEP

Ipc: C12N 15/13 20060101ALI20220928BHEP

Ipc: C12N 15/55 20060101ALI20220928BHEP

Ipc: C12N 9/78 20060101AFI20220928BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230605

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED